14d
First successes in the development of a gene therapy for incurable LAMA2-related muscular dystrophy
Researchers at the University of Basel have developed a gene therapy that could potentially treat a rare and currently fatal ...
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...
Genetic testing can confirm a muscular dystrophy (MD) diagnosis when symptoms and other tests already suggest MD. It also identifies specific gene mutations that can guide targeted treatment. Genetic ...
RENO, NV, UNITED STATES, April 9, 2025 /EINPresswire.com/ -- Sarcomatrix Therapeutics, a privately held biopharmaceutical company advancing transformative therapies ...
The renewal highlights ongoing progress in developing rhLAM-111 for rare muscular diseases, with a new emphasis on Duchenne Muscular Dystrophy. We are excited to have renewed our EU Orphan Drug ...
Hosted on MSN
Muscle regeneration hindered by missing protein in rare muscular dystrophy, study shows
For more than two decades, researchers at the University of Basel, Switzerland, have been investigating a severe form of muscular dystrophy in which muscles progressively degenerate. The research team ...
LONDON (Reuters) - A new stem cell therapy that has enabled dogs with muscular dystrophy to walk more easily could be developed into a treatment to help humans with the disabling illness, Italian ...
More than 30 rare muscular dystrophy types cause progressive muscle weakness from inherited gene mutations. Combined, they affect about 1 in 5,000 to 8,000 people. Common subtypes vary by age of onset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results